Literature DB >> 31119836

Advanced-stage cancer and time to diagnosis: An International Cancer Benchmarking Partnership (ICBP) cross-sectional study.

Marie L Tørring1, Alina Z Falborg2, Henry Jensen2, Richard D Neal3, David Weller4, Irene Reguilon5, Usha Menon6, Peter Vedsted2.   

Abstract

OBJECTIVE: To investigate the relationship between tumour stage at diagnosis and selected components of primary and secondary care in the diagnostic interval for breast, colorectal, lung and ovarian cancers.
METHODS: Observational study based on data from 6,162 newly diagnosed symptomatic cancer patients from Module 4 of the International Cancer Benchmarking Partnership. We analysed the odds of advanced stage of cancer as a flexible function of the length of primary care interval (days from first presentation to referral) and secondary care interval (days from referral to diagnosis), respectively, using logistic regression with restricted cubic splines.
RESULTS: The association between time intervals and stage was similar for each type of cancer. A statistically significant U-shaped association was seen between the secondary care interval and the diagnosis of advanced rather than localised cancer, odds decreasing from the first day onwards and increasing around three and a half months. A different pattern was seen for the primary care interval, flat trends for colorectal and lung cancers and a slightly curved association for ovarian cancer, although not statistically significant.
CONCLUSION: The results confirm previous findings that some cancers may progress even within the relatively short time frame of regulated diagnostic intervals. The study supports the current emphasis on expediting symptomatic diagnosis of cancer.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  bias; breast neoplasms; colorectal neoplasms; delayed diagnosis; diagnosis; early detection of cancer; lung neoplasms; ovarian neoplasms; primary health care; time factors; waiting lists

Mesh:

Year:  2019        PMID: 31119836     DOI: 10.1111/ecc.13100

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  17 in total

1.  p28GANK overexpression is associated with chemotherapy resistance and poor prognosis in ovarian cancer.

Authors:  Ge Yu; Na Li; Wei Wang; Ming Niu; Xiaoling Feng
Journal:  Oncol Lett       Date:  2019-11-13       Impact factor: 2.967

2.  Association of Self-reported Presenting Symptoms With Timeliness of Help-Seeking Among Adolescents and Young Adults With Cancer in the BRIGHTLIGHT Study.

Authors:  Minjoung M Koo; Georgios Lyratzopoulos; Annie Herbert; Gary A Abel; Rachel M Taylor; Julie A Barber; Faith Gibson; Jeremy Whelan; Lorna A Fern
Journal:  JAMA Netw Open       Date:  2020-09-01

3.  Time to diagnosis of symptomatic gastric and oesophageal cancer in the Netherlands: Where is the room for improvement?

Authors:  N F van Erp; C W Helsper; P Slottje; D Brandenbarg; F L Büchner; K M van Asselt; Jwm Muris; M F Kortekaas; Phm Peeters; N J de Wit
Journal:  United European Gastroenterol J       Date:  2020-04-06       Impact factor: 4.623

4.  Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study.

Authors:  Minjoung Monica Koo; Ruth Swann; Sean McPhail; Gary A Abel; Lucy Elliss-Brookes; Greg P Rubin; Georgios Lyratzopoulos
Journal:  Lancet Oncol       Date:  2019-11-06       Impact factor: 41.316

5.  A comparative analysis: international variation in PET-CT service provision in oncology-an International Cancer Benchmarking Partnership study.

Authors:  Charlotte Lynch; Irene Reguilon; Deanna L Langer; Damon Lane; Prithwish De; Wai-Lup Wong; Fergus Mckiddie; Andrew Ross; Lorraine Shack; Thida Win; Christopher Marshall; Mona-Eliszabeth Revheim; Bolette Danckert; John Butler; Sabina Dizdarevic; Cheryl Louzado; Canice Mcgivern; Anne Hazlett; Cindy Chew; Martin O'connell; Samantha Harrison
Journal:  Int J Qual Health Care       Date:  2021-02-20       Impact factor: 2.038

6.  Conceptual Framework to Guide Early Diagnosis Programs for Symptomatic Cancer as Part of Global Cancer Control.

Authors:  Minjoung Monica Koo; Karla Unger-Saldaña; Amos D Mwaka; Marilys Corbex; Ophira Ginsburg; Fiona M Walter; Natalia Calanzani; Jennifer Moodley; Greg P Rubin; Georgios Lyratzopoulos
Journal:  JCO Glob Oncol       Date:  2021-01

7.  An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic.

Authors:  Koen Degeling; Nancy N Baxter; Jon Emery; Mark A Jenkins; Fanny Franchini; Peter Gibbs; G Bruce Mann; Grant McArthur; Benjamin J Solomon; Maarten J IJzerman
Journal:  Asia Pac J Clin Oncol       Date:  2021-02-10       Impact factor: 1.926

8.  Trends in time to cancer diagnosis around the period of changing national guidance on referral of symptomatic patients: A serial cross-sectional study using UK electronic healthcare records from 2006-17.

Authors:  Sarah Price; Anne Spencer; Xiaohui Zhang; Susan Ball; Georgios Lyratzopoulos; Ruben Mujica-Mota; Sal Stapley; Obioha C Ukoumunne; Willie Hamilton
Journal:  Cancer Epidemiol       Date:  2020-09-09       Impact factor: 2.984

9.  SNORA71A Promotes Colorectal Cancer Cell Proliferation, Migration, and Invasion.

Authors:  Zhengxiang Zhang; Yunxiang Tao; Qingling Hua; Juan Cai; Xiaobing Ye; Hao Li
Journal:  Biomed Res Int       Date:  2020-10-05       Impact factor: 3.411

Review 10.  Does changing healthcare use signal opportunities for earlier detection of cancer? A review of studies using information from electronic patient records.

Authors:  Becky White; Cristina Renzi; Meena Rafiq; Gary A Abel; Henry Jensen; Georgios Lyratzopoulos
Journal:  Cancer Epidemiol       Date:  2021-12-04       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.